Publication

Article

Specialty Pharmacy Times

July/August 2014
Volume5
Issue 4

New Biopsy Method More Effective in Revealing Aggressive Prostate Cancer

A new imaging-guided targeted prostate biopsy method was found to be more effective than conventional ultrasound biopsies in revealing aggressive forms of cancer, according to the results of a recent study.

In the study, which appears in the May 19, 2014, issue of Urology, researchers from UCLA found that “blind” biopsies showing prostate cancers presumed to be low risk did not show the true extent of the cancer. The researchers examined 113 men in UCLA’s active surveillance program who were classified as having low-risk cancer based on conventional biopsies.

Using the targeted biopsy method, which combines magnetic resonance imaging with real-time ultrasound, a urologist was able to visualize and target lesions during the procedure. The process creates a virtual map of suspicious areas, which are then placed directly on an ultrasound image during the biopsy.

The researchers found that 36% of patients in the active surveillance program actually had more aggressive cancer than initially thought, which should result in a reevaluation of the criteria for active surveillance, according to the study.

“We are hesitant now to enroll men in active surveillance until they undergo targeted biopsy,” said study senior author Leonard Marks, MD, director of the UCLA active surveillance program, in a press release. “Fusion biopsy will tell us with much greater accuracy than conventional biopsy whether or not they have aggressive disease.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com